Respiratory Disease Testing Market Report 2026

The respiratory disease testing market size has grown strongly in recent years. It will grow from $3.74 billion in 2025 to $3.94 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increasing incidence of chronic respiratory diseases, expansion of hospital diagnostic capabilities, growing awareness of early disease detection, adoption of spirometry testing, increased healthcare screening initiatives.

The respiratory disease testing market size is expected to see strong growth in the next few years. It will grow to $4.93 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to increasing demand for rapid and accurate respiratory diagnostics, rising investments in diagnostic infrastructure, expansion of home-based respiratory testing, growing integration of ai-driven diagnostic tools, increasing focus on population health management. Major trends in the forecast period include increasing adoption of early diagnostic testing solutions, rising use of in-vitro diagnostic respiratory tests, growing integration of digital pulmonary monitoring tools, expansion of point-of-care respiratory testing, enhanced focus on preventive respiratory care.

The increasing prevalence of respiratory diseases is anticipated to drive the growth of the respiratory disease testing market in the coming years. Respiratory diseases include medical conditions that affect the respiratory system, such as the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Respiratory disease testing plays a critical role in the early detection and diagnosis of respiratory conditions, enabling timely treatment and effective disease management. Early diagnosis helps prevent disease progression and is also vital for monitoring and controlling the spread of infectious respiratory illnesses, thereby reducing the risk of severe complications. For example, in June 2025, according to the Office for Health Improvement and Disparities (OHID), a UK-based government department, emergency admissions related to respiratory diseases in England increased by 7% from the financial year ending 2023 to the financial year ending 2024. Therefore, the rising prevalence of respiratory diseases is fueling the growth of the respiratory disease testing market.

Major companies operating in the respiratory disease testing market are concentrating on the development of advanced diagnostic solutions, such as pulmonary function testing technologies, to strengthen their competitive positioning. Pulmonary function tests comprise a series of assessments that evaluate lung capacity, airflow, and overall respiratory performance. For instance, in March 2023, Vitalograph Ltd., a UK-based respiratory diagnostics provider, launched VitaloPFT, a comprehensive pulmonary function testing solution. The VitaloPFT Series delivers advanced respiratory diagnostic capabilities through a range of detailed testing options, offering healthcare providers a cost-effective approach to high-quality respiratory diagnostics. The system features an intuitive, user-friendly interface that simplifies pulmonary function testing workflows for healthcare professionals, improving ease of operation and efficiency.

In January 2023, CAIRE Inc., a US-based medical supply and manufacturing company, acquired MGC Diagnostics Holdings for an undisclosed amount. Through this acquisition, CAIRE aims to expand its product portfolio, diversify revenue streams by incorporating cardiorespiratory diagnostic solutions, and reinforce its position as a leader in respiratory and cardiorespiratory medical technologies. MGC Diagnostics Holdings Inc. is a US-based medical technology company specializing in cardiorespiratory diagnostic solutions and respiratory disease testing products.

Major companies operating in the respiratory disease testing market are Medtronic plc, Abbott Laboratories, Seimens Healthineers AG, Koninklijke Philips N.V., ResMed Inc., Thermo Fisher Scientific Inc., Beckton Dickinson And Company, F. Hoffmann-La Roche Ltd., Nihon Kohden Corporation, GE HealthCare Technologies Inc., Fisher And Paykel Healthcare Corporation Limited, Qiagen N.V., Medical Graphics Corporation, COSMED srl, ndd Medizintechnik AG, Vitalograph Ltd., MGC Diagnostics Corporation, Vyaire Medical Inc., Masimo Corporation, Hamilton Medical AG, Drägerwerk AG & Co. KGaA, Schiller AG, Nonin Medical Inc.

North America was the largest region in the respiratory disease testing market in 2025. Asia-Pacific is expected to be the fastest growing region in the global respiratory disease testing market during the forecast period. The regions covered in the respiratory disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the respiratory disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the respiratory disease testing market by increasing costs of imported diagnostic devices, imaging systems, test kits, reagents, and electronic components used in pulmonary testing. Hospitals and diagnostic laboratories in North America and Europe are most affected due to reliance on imported medical diagnostics, while Asia-Pacific faces higher costs for advanced imaging and testing equipment. These tariffs are increasing procurement costs and slowing equipment upgrades. However, they are also supporting domestic diagnostic manufacturing, local kit production, and regional innovation in respiratory testing technologies.

The respiratory disease testing market research report is one of a series of new reports that provides respiratory disease testing market statistics, including respiratory disease testing industry global market size, regional shares, competitors with a respiratory disease testing market share, detailed respiratory disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory disease testing industry. This respiratory disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Respiratory disease testing refers to the process of evaluating and identifying various respiratory conditions through physical examinations and diagnostic assessments. It helps determine lung function and measure how quickly air can be expelled from the lungs, allowing clinicians to diagnose respiratory diseases even before patients begin to experience symptoms.

The main types of tests involved in respiratory disease testing include imaging tests, mechanical tests, and in vitro diagnostic tests. Imaging tests are a category of diagnostic procedures that produce detailed images of different parts of the body. The products used in respiratory testing include lung volume measurement, imaging systems, spirometry, peak flow meters, blood gas analyzers, and others. These tests are applied in conditions such as chronic obstructive pulmonary disease, lung cancer, asthma, pulmonary tuberculosis, and others, and are conducted in hospitals, physician clinics, clinical laboratories, and other healthcare settings.

The respiratory disease testing market includes revenues earned by entities by providing services such as exhaled nitric oxide tests lung function tests. oxygen therapy, bronchoscopy, ultrasonography, nuclear lung scanning, and pulmonary artery angiography. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.